Data From Phase 3 Pivotal Studies Show Amgen's Novel Investigational Cholesterol-Lowering Medication Evolocumab Significantly

     Data From Phase 3 Pivotal Studies Show Amgen's Novel Investigational
     Cholesterol-Lowering Medication Evolocumab Significantly Reduced LDL
     Cholesterol In Statin Intolerant Patients And In Patients On Statins

Data From Two Separate Phase 3 Studies of Evolocumab (AMG 145), a PCSK9
Inhibitor, Presented in Late-Breaking Clinical Trials Session at ACC.14 - Data
Add to the Three Pivotal Studies Presented Yesterday

Positive Results From GAUSS-2 Simultaneously Published in the Journal of the
American College of Cardiology

Robust Data Presented at ACC.14 From Five Phase 3 Studies in More Than 4,000
Patients Form the Basis of Global Filing Plan

PR Newswire

THOUSAND OAKS, Calif., March 30, 2014

THOUSAND OAKS, Calif., March 30, 2014 /PRNewswire/ --Amgen (NASDAQ: AMGN)
today announced new detailed data from two Phase 3 pivotal studies that showed
treatment with its novel investigational cholesterol-lowering medication,
evolocumab (AMG 145), resulted in a statistically significant reduction in
low-density lipoprotein cholesterol (LDL-C) between 37-39 percent, compared to
ezetimibe in patients with high cholesterol who cannot tolerate statins
(GAUSS-2) and between 55-76 percent compared to placebo when used in
combination with statin therapy in patients with high cholesterol (LAPLACE-2).
Results from the two separate Phase 3 studies, GAUSS-2 and LAPLACE-2, were
presented today as Late-Breaking Clinical Trials and complement the three
Phase 3 studies presented yesterday as Featured Clinical Research at the
American College of Cardiology's 63^rd Annual Scientific Session (ACC.14).
Positive results from the GAUSS-2 study were simultaneously published in the
Journal of the American College of Cardiology.

To view the multimedia assets associated with this release, please click:
http://www.multivu.com/mnr/7061855-amgen-at-american-college-of-cardiology-acc-14-march-30

Object: application/x-shockwave-flash

Evolocumab is an investigational fully human monoclonal antibody that inhibits
proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that reduces
the liver's ability to remove LDL-C from the blood.^1

In the GAUSS-2 study, the most common adverse events (AEs) (≥5 percent in the
combined evolocumab group) were headache, myalgia, pain in extremity and
muscle spasms. In the LAPLACE-2 study, no AEs occurred in ≥2 percent of the
evolocumab combined group. The most common AEs in the evolocumab combined
group (>1.5 percent) were back pain, arthralgia, headache, muscle spasms and
pain in extremity.

"As treatment with statins continues to be an important tool in the management
of high cholesterol, we are encouraged by the positive data from the Phase 3
studies of evolocumab in patients with statin intolerance and in patients
already on statin therapy," said Sean E. Harper, M.D., executive vice
president of Research and Development at Amgen. "We hope that evolocumab will
be able to help patients who are on a moderate or high-intensity statin and
not adequately controlled, as well as patients who cannot tolerate statins and
are in need of an alternate treatment option to help lower their LDL
cholesterol levels."

"Results from the five Phase 3 pivotal studies that we presented at ACC span
more than 4,000 patients and provide us with important insights on the
potential of evolocumab as a treatment for a range of patients at-risk for
cardiovascular disease," Harper added. "We are working closely with regulatory
authorities on our global filing plan in hopes of bringing this new treatment
option to patients with dyslipidemia."

GAUSS-2 (GoalAchievement AfterUtilizing an Anti-PCSK9 Antibody inStatin
IntolerantSubjects-2) Primary Results

  oThe GAUSS-2 study showed that in 307 patients with high cholesterol who
    could not tolerate effective doses of at least two different statins due
    to muscle-related side effects, treatment with subcutaneous evolocumab
    (140 mg every two weeks or 420 mg monthly), significantly reduced mean
    LDL-C by 37-39 percent from baseline compared to ezetimibe (p<0.001).

       oResults of the study showed the mean percent reduction from baseline
         in LDL-C at weeks 10 and 12 were 37 percent for evolocumab 140 mg
         every two weeks and 39 percent for evolocumab 420 mg monthly compared
         to ezetimibe.
       oAt week 12, the percent reduction from baseline in LDL-C was 38
         percent for evolocumab 140 mg every two weeks and 38 percent for
         evolocumab 420 mg monthly compared to ezetimibe.

  oThe most common AEs (>5 percent in evolocumab combined group) were
    headache (7.8 percent evolocumab; 8.8 percent ezetimibe), myalgia (7.8
    percent evolocumab; 17.6 percent ezetimibe), pain in extremity (6.8
    percent evolocumab; 1.0 percent ezetimibe) and muscle spasms (6.3 percent
    evolocumab; 3.9 percent ezetimibe).

"Data from the GAUSS-2 study suggest evolocumab could be a promising
lipid-lowering treatment for patients with high cholesterol who cannot
tolerate effective doses of statins," said GAUSS-2 lead investigator Erik S.G.
Stroes, M.D., chair and professor of the Department of Vascular Medicine at
the Academic Medical Center (AMC), Amsterdam. "The GAUSS-2 results are
encouraging for these patients who are in need of effective lipid-lowering
treatment options."

LAPLACE-2 (LDL-CAssessment withPCSK9MonoclonaLAntibody InhibitionCombined
withStatin ThErapy-2) Primary Results

  oThe LAPLACE-2 study showed that in 1,896 patients with high cholesterol
    (LDL-C >80 mg/dL), treatment with subcutaneous evolocumab (140 mg every
    two weeks or 420 mg monthly) in combination with different daily doses of
    statin therapy significantly reduced mean LDL-C by 55-76 percent from
    baseline compared to placebo and 38-47 percent from baseline compared to
    ezetimibe (p<0.001).

       oResults of the study showed the mean reduction in LDL-C from baseline
         at weeks 10 and 12 was between 66-75 percent for evolocumab 140 mg
         every two weeks versus placebo and between 38-45 percent versus
         ezetimibe, for all statin cohorts.
       oResults of the study also showed the mean percent reduction in LDL-C
         from baseline at weeks 10 and 12 was between 63-75 percent for
         evolocumab 420 mg monthly versus placebo and 44 percent versus
         ezetimibe, for all statin cohorts.
       oAt week 12, the percent reduction from baseline in LDL-C was between
         68-76 percent for evolocumab 140 mg every two weeks and between 55-71
         percent for evolocumab 420 mg monthly, compared to placebo, for all
         statin cohorts. Compared with ezetimibe, evolocumab reduced LDL-C
         from baseline between 40-47 percent when dosed every two weeks and
         between 39-41 percent when dosed monthly, for all statin cohorts.

  oNo AEs occurred in ≥2 percent of the evolocumab combined group. The most
    common AEs in the evolocumab combined group were back pain (1.8 percent
    evolocumab; 3.2 percent ezetimibe; 2.5 percent placebo), arthralgia (1.7
    percent evolocumab; 1.8 percent ezetimibe; 1.6 percent placebo), headache
    (1.7 percent evolocumab; 2.3 percent ezetimibe; 2.7 percent placebo),
    muscle spasms (1.5 percent evolocumab; 2.7 percent ezetimibe; 1.1 percent
    placebo) and pain in extremity (1.5 percent evolocumab; 1.4 percent
    ezetimibe; 1.3 percent placebo).

"The positive results from the LAPLACE-2 study show that adding evolocumab to
statin therapy additionally lowers LDL cholesterol levels when added to
moderate or high doses of statins," said LAPLACE-2 lead investigator Jennifer
G. Robinson, M.D., M.P.H., director of the Prevention Intervention Center,
professor of the Departments of Epidemiology & Medicine, College of Public
Health at the University of Iowa. "While statins are effective in reducing LDL
cholesterol levels and the risk of heart attack and stroke, some patients
still need more LDL- lowering treatment options."

High cholesterol is the most common form of dyslipidemia, which is an
abnormality of lipids in the blood.^2,3 There are approximately 300 million
cases of dyslipidemia in the U.S., Japan and Western Europe.^4 According to
the Centers for Disease Control and Prevention, more than 71 million American
adults have high LDL-C^5, or "bad" cholesterol, and elevated LDL-C is
recognized as a major risk factor for cardiovascular disease.^6,7

Amgen will also host a webcast investor meeting at ACC.14 on Sunday, March 30,
at 7 p.m. EDT. Sean E. Harper, M.D., executive vice president of Research and
Development at Amgen, along with members of Amgen's clinical development team
and clinical investigators, will participate at the investor meeting to
discuss Amgen's cardiovascular program, including the primary analyses of five
Phase 3 evolocumab studies being presented at ACC.14.

Live audio of the investor meeting will be simultaneously broadcast over the
Internet and will be available to members of the news media, investors and the
general public.

The webcast, as with other selected presentations regarding developments in
Amgen's business given by management at certain investor and medical
conferences, can be found on Amgen's website, www.amgen.com, under Investors.
Information regarding presentation times, webcast availability and webcast
links are noted on Amgen's Investor Relations Events Calendar. The webcast
will be archived and available for replay for at least 90 days after the
event.

GAUSS-2 Study Design
GAUSS-2 (GoalAchievement AfterUtilizing an Anti-PCSK9 Antibody inStatin
IntolerantSubjects-2) is a Phase 3 randomized, multicenter, double-blind,
placebo- and ezetimibe-controlled trial designed to evaluate the safety,
tolerability and efficacy of evolocumab in 307 hyperlipidemic patients who
could not tolerate effective doses of at least two different statins due to
muscle-related side effects. Patients were randomized to one of four treatment
groups: subcutaneous evolocumab 140 mg every two weeks and oral placebo daily;
subcutaneous evolocumab 420 mg monthly and oral placebo daily; subcutaneous
placebo every two weeks and oral ezetimibe 10 mg daily; or subcutaneous
placebo monthly and oral ezetimibe 10 mg daily. The co-primary endpoints were
the percent reduction from baseline in LDL-C at week 12 and the mean percent
reduction from baseline in LDL-C at weeks 10 and 12.Secondary efficacy
endpoints included means at weeks 10 and 12 and at week 12 for the following:
absolute change from baseline in LDL-C; LDL-C <70 mg/dL; and the percentage
change from baseline in non-high-density lipoprotein cholesterol (non-HDL-C),
apolipoprotein B (ApoB), total cholesterol (TC)/HDL-C ratio,
ApoB/apolipoprotein A1 (ApoA1) ratio, lipoprotein(a), triglycerides, HDL-C and
very low-density lipoprotein cholesterol (VLDL-C).

LAPLACE-2 Study Design
LAPLACE-2 (LDL-CAssessment withPCSK9MonoclonaLAntibody InhibitionCombined
with Statin ThErapy-2) is a Phase 3 randomized, multicenter, double-blind,
placebo- and ezetimibe-controlled study designed to evaluate safety,
tolerability and efficacy of evolocumab in 1,896 patients with primary
hypercholesterolemia and mixed dyslipidemia (LDL-C≥80 mg/dL) when added to
statin therapy. Patients were randomized to one of 24 treatment groups in a
two-step randomization. Eligible patients were initially randomized to one of
five open label background statin treatments: atorvastatin 10 mg, atorvastatin
80 mg, rosuvastatin 5 mg, rosuvastatin 40 mg or simvastatin 40 mg daily.
Patients randomized to atorvastatin were then randomized to one of six
treatment groups: evolocumab every two weeks and oral placebo, evolocumab
every month and oral placebo, subcutaneous placebo every two weeks and oral
placebo, subcutaneous placebo every month and oral placebo, subcutaneous
placebo every two weeks and ezetimibe 10 mg, or subcutaneous placebo every
month and ezetimibe 10 mg. Patients randomized to rosuvastatin or simvastatin
were then randomized to one of four treatment groups: evolocumab every two
weeks, evolocumab every month, subcutaneous placebo every two weeks, or
subcutaneous placebo every month.

The co-primary endpoints were the mean percent change from baseline in LDL-C
at weeks 10 and 12 and the percent change in LDL-C reduction at week
12.Co-secondary efficacy endpoints included means at weeks 10 and 12 and at
week 12 for the following: LDL-C <70 mg/dL; absolute change from baseline in
LDL-C; and the percentage change from baseline in non-high-density lipoprotein
cholesterol (non-HDL-C), apolipoprotein B (ApoB), total cholesterol (TC)/HDL-C
ratio, ApoB/apolipoprotein A1 (ApoA1) ratio, lipoprotein(a), triglycerides,
HDL-C and very low-density lipoprotein cholesterol (VLDL-C).

About Evolocumab
Evolocumab is a fully human monoclonal antibody that inhibits proprotein
convertase subtilisin/kexin type 9 (PCSK9).^1 PCSK9 is a protein that targets
LDL receptors for degradation and thereby reduces the liver's ability to
remove LDL-C, or "bad" cholesterol, from the blood.^8 Evolocumab, being
developed by Amgen scientists, is designed to bind to PCSK9 and inhibit PCSK9
from binding to LDL receptors on the liver surface. In the absence of PCSK9,
there are more LDL receptors on the surface of the liver to remove LDL-C from
the blood.^1

About PROFICIO: The Evolocumab Clinical Trial Program
PROFICIO, which stands for the Program to Reduce LDL-C and Cardiovascular
Outcomes Following Inhibition of PCSK9 In Different POpulations, is a large
and comprehensive clinical trial program evaluating evolocumab in 20 clinical
trials, with a combined planned enrollment of nearly 30,000 patients.

The Phase 3 program includes 14 trials to evaluate evolocumab administered
every two weeks and monthly in multiple patient populations, including in
combination with statins in patients with hyperlipidemia (LAPLACE-2 and
YUKAWA-2); in patients with hyperlipidemia who cannot tolerate statins
(GAUSS-2 and GAUSS-3); as a stand-alone treatment in patients with
hyperlipidemia (MENDEL-2); in patients whose elevated cholesterol is caused by
genetic disorders called heterozygous (RUTHERFORD-2 and TAUSSIG) and
homozygous (TESLA and TAUSSIG) familial hypercholesterolemia; as well as the
administration of evolocumab (THOMAS-1 and THOMAS-2).

Five studies in the evolocumab Phase 3 program will provide long-term safety
and efficacy data. These include FOURIER (Further
CardiovascularOUtcomesResearch with PCSK9Inhibition in Subjects
withElevatedRisk), which will assess whether treatment with evolocumab in
combination with statin therapy compared to placebo and statin therapy reduces
recurrent cardiovascular events in approximately 22,500 patients with
cardiovascular disease; DESCARTES (DurableEffect of PCSK9 AntibodyCompARed
wiTh PlacEbo Study) in patients with hyperlipidemia at risk for cardiovascular
disease; OSLER-2 (Open Label Study of Long TERm Evaluation Against LDL-C
Trial-2) in patients with high cholesterol who completed any of the Phase 3
studies; GLAGOV (GLobal Assessment of Plaque ReGression with a PCSK9 AntibOdy
as Measured by IntraVascular Ultrasound), which will determine the effect of
evolocumab on coronary atherosclerosis in approximately 950 patients
undergoing cardiac catheterization; and TAUSSIG (Trial Assessing Long Term USe
of PCSK9 Inhibition in Subjects with Genetic LDL Disorders), which will assess
the long-term safety and efficacy of evolocumab on LDL-C in patients with
severe familial hypercholesterolemia.

About Amgen's Commitment to Cardiovascular Disease
Amgen is dedicated to addressing important scientific questions in order to
advance care and improve the lives of patients with cardiovascular disease.
Through its own research and development efforts and innovative partnerships,
Amgen has built a robust cardiology pipeline consisting of several
investigational molecules in an effort to address a number of today's
important unmet patient needs, such as high cholesterol and heart failure.

About Amgen
Amgen is committed to unlocking the potential of biology for patients
suffering from serious illnesses by discovering, developing, manufacturing and
delivering innovative human therapeutics. This approach begins by using tools
like advanced human genetics to unravel the complexities of disease and
understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its biologics
manufacturing expertise to strive for solutions that improve health outcomes
and dramatically improve people's lives. A biotechnology pioneer since 1980,
Amgen has grown to be the world's largest independent biotechnology company,
has reached millions of patients around the world and is developing a pipeline
of medicines with breakaway potential.

For more information, visit www.amgen.com and follow us on
www.twitter.com/amgen.

Forward-Looking Statements
This news release contains forward-looking statements that are based on
management's current expectations and beliefs and are subject to a number of
risks, uncertainties and assumptions that could cause actual results to differ
materially from those described. All statements, other than statements of
historical fact, are statements that could be deemed forward-looking
statements, including estimates of revenues, operating margins, capital
expenditures, cash, other financial metrics, expected legal, arbitration,
political, regulatory or clinical results or practices, customer and
prescriber patterns or practices, reimbursement activities and outcomes and
other such estimates and results. Forward-looking statements involve
significant risks and uncertainties, including those discussed below and more
fully described in theSecurities and Exchange Commission(SEC) reports filed
byAmgen, includingAmgen'smost recent annual report on Form 10-K and any
subsequent periodic reports on Form 10-Q and Form 8-K. Please refer
toAmgen'smost recent Forms 10-K, 10-Q and 8-K for additional information on
the uncertainties and risk factors related to our business. Unless otherwise
noted, Amgenis providing this information as ofMarch 30, 2014, and expressly
disclaims any duty to update information contained in this news release.

No forward-looking statement can be guaranteed and actual results may differ
materially from those Amgen Inc. and its subsidiaries (which are collectively
referred to as we, or us) project. Discovery or identification of new product
candidates or development of new indications for existing products cannot be
guaranteed and movement from concept to product is uncertain; consequently,
there can be no guarantee that any particular product candidate or development
of a new indication for an existing product will be successful and become a
commercial product. Further, preclinical results do not guarantee safe and
effective performance of product candidates in humans. The complexity of the
human body cannot be perfectly, or sometimes, even adequately modeled by
computer or cell culture systems or animal models. The length of time that it
takes for us and our partners to complete clinical trials and obtain
regulatory approval for product marketing has in the past varied and we expect
similar variability in the future. We develop product candidates internally
and through licensing collaborations, partnerships and joint ventures. Product
candidates that are derived from relationships may be subject to disputes
between the parties or may prove to be not as effective or as safe as we may
have believed at the time of entering into such relationship. Also, we or
others could identify safety, side effects or manufacturing problems with our
products after they are on the market. Our business may be impacted by
government investigations, litigation and product liability claims. If we fail
to meet the compliance obligations in the corporate integrity agreement
between us and the U.S. government, we could become subject to significant
sanctions. We depend on third parties for a significant portion of our
manufacturing capacity for the supply of certain of our current and future
products and limits on supply may constrain sales of certain of our current
products and product candidate development.

In addition, sales of our products (including products of our wholly-owned
subsidiaries) are affected by the reimbursement policies imposed by
third-party payers, including governments, private insurance plans and managed
care providers and may be affected by regulatory, clinical and guideline
developments and domestic and international trends toward managed care and
healthcare cost containment as well as U.S. legislation affecting
pharmaceutical pricing and reimbursement. Government and others' regulations
and reimbursement policies may affect the development, usage and pricing of
our products. In addition, we compete with other companies with respect to
some of our marketed products as well as for the discovery and development of
new products. We believe that some of our newer products, product candidates
or new indications for existing products, may face competition when and as
they are approved and marketed. Our products may compete against products that
have lower prices, established reimbursement, superior performance, are easier
to administer, or that are otherwise competitive with our products. In
addition, while we and our partners routinely obtain patents for products and
technology, the protection of our products offered by patents and patent
applications may be challenged, invalidated or circumvented by our competitors
and there can be no guarantee of our or our partners' ability to obtain or
maintain patent protection for our products or product candidates. We cannot
guarantee that we will be able to produce commercially successful products or
maintain the commercial success of our existing products. Our stock price may
be affected by actual or perceived market opportunity, competitive position,
and success or failure of our products or product candidates. Further, the
discovery of significant problems with a product similar to one of our
products that implicate an entire class of products could have a material
adverse effect on sales of the affected products and on our business and
results of operations. Our efforts to integrate the operations of companies we
have acquired may not be successful.

The scientific information discussed in this news release related to our
product candidates is preliminary and investigative. Such product candidates
are not approved by theU.S. Food and Drug Administration(FDA), and no
conclusions can or should be drawn regarding the safety or effectiveness of
the product candidates.

CONTACT: Amgen
Wendy Woods Williams, 805-341-5797 (media)
Arvind Sood, 805-447-1060 (investors)

References

1.Amgen Data on File, Investigator Brochure.
2.World Health Organization. Quantifying Selected Major Risks to Health. In:
    The World Health Report 2002 - Reducing Risks, Promoting Healthy Life.
    Chapter 4: Geneva: World Health Organization;202:47-97.
3.Merck Manuals website.
    http://www.merckmanuals.com/professional/endocrine_and_metabolic_disorders/lipid_disorders/dyslipidemia.html.
    Accessed March 2014.
4.National Institute of Health (2006). Federal Register Volume 74 (250).
    Washington, DC: U.S. Government Printing Office.
    http://www.gpo.gov/fdsys/pkg/FR-2009-12-31/html/E9-31072.htm. Accessed
    March 2014.
5.CDC Morbidity and Mortality Weekly Report. Vital Signs: Prevalence,
    Treatment, and Control of High Levels of Low-Density Lipoprotein
    Cholesterol --- United States, 1999--2002 and 2005-2008. February 4, 2011.
    Available at:
    http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6004a5.htm?s_cid=mm6004a5_w.
    Accessed March 2014.
6.American Heart Association (2012). Why cholesterol matters.
    http://www.heart.org/HEARTORG/Conditions/Cholesterol/WhyCholesterolMatters/Why-Cholesterol-Matters_UCM_001212_Article.jsp.
    Accessed March 2014.
7.World Health Organization. Global status report on noncommunicable
    diseases 2010. Geneva, 2011.
8.Abifadel M et al. Nat Genet. 2003;34:154-156.



U.S. Burden of Cardiovascular Disease Infographic



Amgen Logo.



To view the multimedia assets associated with this release, please click:
http://www.multivu.com/mnr/7061855-amgen-at-american-college-of-cardiology-acc-14-march-30

SOURCE Amgen

Website: http://www.amgen.com
 
Press spacebar to pause and continue. Press esc to stop.